Antibodies that bind cell-associated ca 125/o772p
AssigneePurdue Pharma L.P.
InventorsEarl F. ALBONE, Daniel A. Soltis
Life of this patent
Estimating the term…
Loading patent…
AssigneePurdue Pharma L.P.
InventorsEarl F. ALBONE, Daniel A. Soltis
Estimating the term…
The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a CA 125/O772P-related disorder. In particular, the present invention provides methods of preventing, managing, treating, or ameliorating one or more symptoms associated with a cell proliferative disorder, such as cancer, e.g., ovarian cancer. The present invention still further provides methods for diagnosing a CA 125/O772P-related disorder or predisposition to developing such a disorder, as well as methods for identifying antibodies, and antigen-binding fragments of antibodies, that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides.
An isolated monoclonal antibody, or an antigen-binding antibody fragment, that binds to the amino acid sequence from residues 14-452 of SEQ M NO:1, wherein the antibody preferentially binds cell-associated CA 125/O772P polypeptide relative to shed CA 125/O772P polypeptide.
Dependencies are inferred from the claim text.